Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Ophthalmology
Published in: International Ophthalmology 1/2012

01-02-2012 | Case Report

Topical beta-blocker treatment for migraine

Author: Patrick J. T. Chiam

Published in: International Ophthalmology | Issue 1/2012

Login to get access

Abstract

Beta-blockers are a well-known prophylactic treatment for migraine; however, treatment by the ocular route has not been widely considered. This case illustrates the resolution of a visual field defect associated with migraine and improvement of symptoms possibly due to administration of a topical beta-blocker. This novel method of treatment especially when visual field defects are present may have a place in the management of migraine.
Literature
1.
Comoglu S, Yarangumeli A, Gurbuz Koz O, Halil Elhan A, Kural G (2003) Glaucomatous visual field defects in patients with migraine. J Neurol 250(2):201–206PubMedCrossRef
2.
McKendrick AM, Vingrys AJ, Badcock DR, Heywood JT (2000) Visual field losses in subjects with migraine headaches. Invest Ophthalmol Vis Sci 41(5):1239–1247PubMed
3.
Connor RCR (1962) Complicated migraine: a study of permanent neurological and visual defects caused by migraine. Lancet 2:1072–1075PubMedCrossRef
4.
Sheddan AH, Laurence J, Barrish A, Olah TV (2001) Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Doc Ophthalmol 103(1):73–79CrossRef
5.
6.
Ishikawa H, Yoshihara M, Mizuki K, Kashima Y (2000) A pediatric case of ophthalmoplegic migraine with recurrent oculomotor nerve palsy. Jpn J Ophthalmol 44(5):576PubMedCrossRef
7.
Gross RL, Hensley SH, Gao F, Wu SM (1999) Retinal ganglion cell dysfunction induced by hypoxia and glutamate: potential neuroprotective effects of beta-blockers. Surv Ophthalmol 43(1):S162–S170PubMedCrossRef
Metadata
Title
Topical beta-blocker treatment for migraine
Author
Patrick J. T. Chiam
Publication date
01-02-2012
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 1/2012
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-012-9516-6

Other articles of this Issue 1/2012

International Ophthalmology 1/2012 Go to the issue

Original Paper

The relationship between optical coherence tomography patterns, angiographic parameters and visual acuity in age-related macular degeneration

Case Report

Primary cutaneous adenoid cystic carcinoma of the upper lid: a case report and literature review

Letter to the Editor

Surgical intervention for corneal involvement in xeroderma pigmentosa

Case Report

Choroidal tuberculoma in a patient with ocular Behçet disease

Case Report

Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma

Case Report

Boston keratoprosthesis restoring vision in an unusual case of end-stage limbal stem cell deficiency following exposure to Euphorbia latex